Flexible Buprenorphine/Naloxone Model of Care for Reducing Opioid Use in Individuals With Prescription-Type Opioid Use Disorder: An Open-Label, Pragmatic, Noninferiority Randomized Controlled Trial
PsiquiatriaSobre o estudo
- Desenho
- Ensaio clínico randomizado
- Nível de evidência
- 2 · Nova evidência
- Revista
- The American journal of psychiatry
- Publicado em
- 15 jun 2022
- Citações
- 0
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Flexible Buprenorphine/Naloxone Model of Care for Reducing Opioid Use in Individuals With Prescription-Type Opioid Use Disorder: An Open-Label, Pragmatic, Noninferiority Randomized Controlled Trial
Didier Jutras-Aswad, Bernard Le Foll, Keith Ahamad, Ron Lim, Julie Bruneau, Benedikt Fischer, Jürgen Rehm, T Cameron Wild, Evan Wood, Suzanne Brissette et al.
Descritores MeSH
- Buprenorphine
- Opioid-Related Disorders
- Drug Overdose
- Canada
- Female
- Humans
- Buprenorphine, Naloxone Drug Combination
- Methadone
- Narcotic Antagonists
- Prescriptions
Veja também
Estudos relacionados
- Opioid agonist treatment outcomes among individuals with a history of nonfatal overdose: Findings from a pragmatic, pan-Canadian, randomized control trial
- Associations of methadone and buprenorphine-naloxone doses with unregulated opioid use, treatment retention, and adverse events in prescription-type opioid use disorders: Exploratory analyses of the OPTIMA study
- Effects of Buprenorphine/Naloxone and Methadone on Depressive Symptoms in People with Prescription Opioid Use Disorder: A Pragmatic Randomised Controlled Trial
- Mediating effect of craving on the impact of buprenorphine/naloxone and methadone treatment on opioid use: Results from a randomized controlled trial